{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:29:24Z","timestamp":1765546164338,"version":"3.37.3"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1111\/jcpt.12516","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T05:22:41Z","timestamp":1489555361000},"page":"311-317","source":"Crossref","is-referenced-by-count":9,"title":["National trends in the treatment of diabetic nephropathy in the United States"],"prefix":"10.1155","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6115-7568","authenticated-orcid":false,"given":"O.","family":"Ajiboye","sequence":"first","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health; Baltimore MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. B.","family":"Segal","sequence":"additional","affiliation":[{"name":"Center for Drug Safety and Effectiveness; Johns Hopkins Bloomberg School of Public Health; Baltimore MD USA"},{"name":"Division of General Internal Medicine; Johns Hopkins Hospital; Baltimore MD USA"},{"name":"Department of Epidemiology; Johns Hopkins Bloomberg School of Public Health; Baltimore MD USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"key":"10.1111\/jcpt.12516-BIB0001|jcpt12516-cit-0001","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/pop.2015.0181","article-title":"Insights from yesterday, today, and future trends","volume":"20","author":"Rowley","year":"2017","journal-title":"Popul Health Manag"},{"key":"10.1111\/jcpt.12516-BIB0002|jcpt12516-cit-0002","unstructured":"Colby SL Ortman JM Projections of the Size and Composition of the U.S. Population: 2014 to 2060, Current Population Reports, P25-1143, U.S. Washington, DC Census Bureau 2014"},{"key":"10.1111\/jcpt.12516-BIB0003|jcpt12516-cit-0003","first-page":"918","article-title":"Increasing prevalence of diagnosed diabetes-United States and Puerto Rico, 1995-2010","volume":"61","author":"Centers for Disease Control and Prevention (CDC)","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1111\/jcpt.12516-BIB0004|jcpt12516-cit-0004","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1136\/bmj.38237.585000.7C","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","author":"Strippoli","year":"2004","journal-title":"BMJ"},{"key":"10.1111\/jcpt.12516-BIB0005|jcpt12516-cit-0005","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1172\/JCI72271","article-title":"Molecular mechanisms of diabetic kidney disease","volume":"124","author":"Reidy","year":"2014","journal-title":"J Clin Invest"},{"issue":"Suppl. 12","key":"10.1111\/jcpt.12516-BIB0006|jcpt12516-cit-0006","first-page":"S23","article-title":"Emerging therapeutic strategies in diabetic nephropathy","volume":"20","author":"Ravera","year":"2007","journal-title":"J Nephrol"},{"key":"10.1111\/jcpt.12516-BIB0007|jcpt12516-cit-0007","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/MNH.0000000000000214","article-title":"New and old agents in the management of diabetic nephropathy","volume":"25","author":"Lytvyn","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1111\/jcpt.12516-BIB0008|jcpt12516-cit-0008","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/ndt\/17.9.1543","article-title":"The role of genetic susceptibility in diabetic nephropathy: evidence from family studies","volume":"17","author":"Fava","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/jcpt.12516-BIB0009|jcpt12516-cit-0009","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.2215\/CJN.02560607","article-title":"Genetic factors in diabetic nephropathy","volume":"2","author":"Freedman","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/jcpt.12516-BIB0010|jcpt12516-cit-0010","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1097\/HJH.0000000000001051","article-title":"Paternal programming of offspring cardiometabolic diseases in later life","volume":"34","author":"Li","year":"2016","journal-title":"J Hypertens"},{"key":"10.1111\/jcpt.12516-BIB0011|jcpt12516-cit-0011","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/MCO.0000000000000177","article-title":"Developmental programming of type 2 diabetes: early nutrition and epigenetic mechanisms","volume":"18","author":"Ong","year":"2015","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1111\/jcpt.12516-BIB0012|jcpt12516-cit-0012","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11255-015-1121-y","article-title":"Diabetic nephropathy: What does the future hold?","volume":"48","author":"Montero","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1111\/jcpt.12516-BIB0013|jcpt12516-cit-0013","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s11606-009-1242-z","article-title":"High-risk diabetic patients in medicare part D programs: Are they getting the recommended ACEI\/ARB therapy?","volume":"25","author":"Yang","year":"2010","journal-title":"J Gen Intern Med"},{"key":"10.1111\/jcpt.12516-BIB0014|jcpt12516-cit-0014","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1001\/archinte.168.19.2088","article-title":"National trends in treatment of type 2 diabetes mellitus, 1994-2007","volume":"168","author":"Alexander","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1111\/jcpt.12516-BIB0015|jcpt12516-cit-0015","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/jdi.12380","article-title":"Renoprotective effects of incretin-based drugs: a novel pleiotropic effect of dipeptidyl peptidase-4 inhibitor","volume":"7","author":"Kodera","year":"2016","journal-title":"J Diabetes Investig"},{"key":"10.1111\/jcpt.12516-BIB0016|jcpt12516-cit-0016","unstructured":"Bolen S Tseng E Hutfless S et al Diabetes Medications for Adults with Type 2 Diabetes: An Update Comparative Effectiveness Review No. 173 (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-2012-00007-I.) AHRQ Publication No. 16-EHC013-EF. Rockville, MD: Agency for Healthcare Research and Quality 2016"},{"key":"10.1111\/jcpt.12516-BIB0017|jcpt12516-cit-0017","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.2337\/diacare.26.6.1847","article-title":"Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes","volume":"26","author":"Cohen","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12516-BIB0018|jcpt12516-cit-0018","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2337\/dc13-2289","article-title":"Use of antidiabetic drugs in the U.S., 2003-2012","volume":"37","author":"Hampp","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12516-BIB0019|jcpt12516-cit-0019","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2337\/dc13-2097","article-title":"Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012","volume":"37","author":"Turner","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1111\/jcpt.12516-BIB0020|jcpt12516-cit-0020","unstructured":"IMS Health National Disease and Therapeutic Index (NDTI) 2014 1 37"},{"key":"10.1111\/jcpt.12516-BIB0021|jcpt12516-cit-0021","unstructured":"American Diabetes Association Diabetes Among Hispanics: All are not Equal: American Diabetes Association \u00ae 2016 http:\/\/www.diabetes.org\/newsroom\/press-releases\/2014\/diabetes-among-hispanics-all-are-not-equal.html"},{"key":"10.1111\/jcpt.12516-BIB0022|jcpt12516-cit-0022","unstructured":"Brown A The U.S. Hispanic Population has Increased Sixfold Since 1970 | Pew Research Center 2016 http:\/\/www.pewresearch.org\/fact-tank\/2014\/02\/26\/the-u-s-hispanic-population-has-increased-sixfold-since-1970\/"},{"key":"10.1111\/jcpt.12516-BIB0023|jcpt12516-cit-0023","unstructured":"HHS Press Office 20 Million People have Gained Health Insurance Coverage Because of the Affordable Care Act, New Estimates Show | HHS.gov 2016 http:\/\/www.hhs.gov\/about\/news\/2016\/03\/03\/20-million-people-have-gained-health-insurance-coverage-because-affordable-care-act-new-estimates"},{"key":"10.1111\/jcpt.12516-BIB0024|jcpt12516-cit-0024","unstructured":"Centers for Disease Control and Prevention (CDC) National Surveillance: Diagnosed Diabetes. Diabetes Public Health Resource. [Diabetes] 2015 http:\/\/www.cdc.gov\/diabetes\/statistics\/esrd\/fig5.htm"},{"key":"10.1111\/jcpt.12516-BIB0025|jcpt12516-cit-0025","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.whi.2007.03.003","article-title":"Gender and racial disparities in the management of diabetes mellitus among medicare patients","volume":"17","author":"Chou","year":"2007","journal-title":"Womens Health Issues"},{"key":"10.1111\/jcpt.12516-BIB0026|jcpt12516-cit-0026","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1517\/13543784.17.10.1487","article-title":"Investigational drugs for diabetic nephropathy","volume":"17","author":"Cortinovis","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/jcpt.12516-BIB0027|jcpt12516-cit-0027","doi-asserted-by":"publisher","first-page":"381713","DOI":"10.1155\/2012\/381713","article-title":"Choosing between GLP-1 receptor agonists and DPP-4 inhibitors: a pharmacological perspective","volume":"2012","author":"Brown","year":"2012","journal-title":"J Nutr Metab"},{"key":"10.1111\/jcpt.12516-BIB0028|jcpt12516-cit-0028","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1345\/aph.1R444","article-title":"Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors","volume":"47","author":"Boland","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1111\/jcpt.12516-BIB0029|jcpt12516-cit-0029","unstructured":"US Food and Drug Administration Drug Safety and Availability > FDA Drug Safety Communication: FDA Strengthens Kidney Warnings for Diabetes Medicines Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR) 2016 http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm505860.htm"},{"key":"10.1111\/jcpt.12516-BIB0030|jcpt12516-cit-0030","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12516-BIB0031|jcpt12516-cit-0031","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00125-011-2398-8","article-title":"Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis","volume":"55","author":"Vejakama","year":"2012","journal-title":"Diabetologia"},{"key":"10.1111\/jcpt.12516-BIB0032|jcpt12516-cit-0032","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1525-1497.2005.0170.x","article-title":"Patterns of antihypertensive therapy among patients with diabetes","volume":"20","author":"Johnson","year":"2005","journal-title":"J Gen Intern Med"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12516","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12516\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:02:40Z","timestamp":1671818560000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,15]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12516","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"type":"print","value":"0269-4727"}],"subject":[],"published":{"date-parts":[[2017,3,15]]}}}